Dr Zsuzanna Tabi
Teams and roles for Zsuzanna Tabi
Publication
2022
2021
2018
2017
2016
- Al-Taei, S. et al. 2016. Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: self-amplifying immunosuppression in cancer. OncoImmunology 6 (2), pp.312-318. e1268308. (10.1080/2162402X.2016.1268308)
- Codd, A. , Al-Taei, S. and Tabi, Z. 2016. Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies. Annals of Translational Medicine 4 (S1), pp.S56. (10.21037/atm.2016.10.30)
- Welton, J. L. et al., 2016. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. Journal of Extracellular Vesicles 5 31209. (10.3402/jev.v5.31209)
- Webber, J. P. et al. 2016. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget 7 , pp.20124-20139. (10.18632/oncotarget.7716)
- Morgan, R. et al., 2016. HOX transcription factors are potential targets and markers in malignant mesothelioma. BMC Cancer 16 (1) 85. (10.1186/s12885-016-2106-7)
- Rintoul, R. C. et al., 2016. MesobanK UK: an international mesothelioma bioresource. Thorax 71 (4), pp.380-382. (10.1136/thoraxjnl-2015-207496)
2015
2014
2013
2012
2011
2010
2009
- Mitchell, P. J. et al. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7 (4), pp.n/a. (10.1186/1479-5876-7-4)
- Navabi, H. et al., 2009. A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27 (1), pp.107-115. (10.1016/j.vaccine.2008.10.024)
- Renneson, J. et al., 2009. IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection. European Journal of Immunology 39 (10), pp.2789-2799. (10.1002/eji.200939414)
- Tabi, Z. 2009. Cancer vaccines. In: Lu, Y. and Mahato, R. I. eds. Pharmaceutical Perspectives of Cancer Therapeutics. London: Springer. , pp.365-368.
2008
- Clayton, A. et al. 2008. Human tumor-derived exosomes down-modulate NKG2D expression. Journal of Immunology 180 (11), pp.7249-7258.
- Coleman, S. L. et al. 2008. SV40 large T antigen-specific human T cell memory responses. Journal of Medical Virology 80 (8), pp.1497-1504. (10.1002/jmv.21216)
- Mitchell, J. P. et al. 2008. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. Journal of Immunological Methods 335 (1-2), pp.98-105. (10.1016/j.jim.2008.03.001)
- Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2.Springer. , pp.129-160. (10.1007/978-1-4020-8442-3)
2007
2005
- Clayton, A. et al. 2005. Induction of heat shock proteins in B-cell exosomes. Journal of Cell Science 118 (16), pp.3631-3638. (10.1242/jcs.02494)
- Coleman, S. L. et al. 2005. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Research 65 (15), pp.7000-7006. (10.1158/0008-5472.CAN-04-3792)
- Adams, M. et al., 2005. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23 (17-18), pp.2374-2378. (10.1016/j.vaccine.2005.01.014)
- Navabi, H. et al., 2005. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells, Molecules, and Diseases 35 (2), pp.149-152. (10.1016/j.bcmd.2005.06.008)
- Jasani, B. et al. 2005. Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. Vaccine 23 (17-18), pp.2339-2402. (10.1016/j.vaccine.2005.01.019)
- Clayton, A. and Tabi, Z. 2005. Exosomes and the MICA-NKG2D system in cancer. Blood Cells, Molecules, and Diseases 34 (3), pp.206-213. (10.1016/j.bcmd.2005.03.003)
2004
2002
2001
Articles
- Knight, R. et al. 2022. Oral progenitor cell line-derived small extracellular vesicles as a treatment for preferential wound healing outcome. Stem Cells Translational Medicine 11 (8), pp.861-875. (10.1093/stcltm/szac037)
- Evans, L. et al. 2021. Macrophage plasticity and function in the lung tumour microenvironment revealed in 3D heterotypic spheroid and explant models. Biomedicines 9 (3) 302. (10.3390/biomedicines9030302)
- Hill, K. , Portman, M. and Tabi, Z. 2018. Meet the researchers: an alternative method of engaging patients with research in mesothelioma. Research Involvement and Engagement 4 (1) 33. (10.1186/s40900-018-0119-x)
- Codd, A. S. et al. 2018. Cancer stem cells as targets for immunotherapy. Immunology 153 (3), pp.304-314. (10.1111/imm.12866)
- Lester, J. F. et al. 2018. A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. OncoImmunology 7 (12) e1457597. (10.1080/2162402X.2018.1457597)
- Salimu, J. et al., 2017. Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. Journal of Extracellular Vesicles 6 (1) 1368823. (10.1080/20013078.2017.1368823)
- Al-Taei, S. et al. 2016. Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: self-amplifying immunosuppression in cancer. OncoImmunology 6 (2), pp.312-318. e1268308. (10.1080/2162402X.2016.1268308)
- Codd, A. , Al-Taei, S. and Tabi, Z. 2016. Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies. Annals of Translational Medicine 4 (S1), pp.S56. (10.21037/atm.2016.10.30)
- Welton, J. L. et al., 2016. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. Journal of Extracellular Vesicles 5 31209. (10.3402/jev.v5.31209)
- Webber, J. P. et al. 2016. Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. Oncotarget 7 , pp.20124-20139. (10.18632/oncotarget.7716)
- Morgan, R. et al., 2016. HOX transcription factors are potential targets and markers in malignant mesothelioma. BMC Cancer 16 (1) 85. (10.1186/s12885-016-2106-7)
- Rintoul, R. C. et al., 2016. MesobanK UK: an international mesothelioma bioresource. Thorax 71 (4), pp.380-382. (10.1136/thoraxjnl-2015-207496)
- Salimu, J. et al. 2015. Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells—A Key Role for Heat-Shock Protein 70 and Receptor CD91. Cancer Immunology Research 3 (6), pp.678-688. (10.1158/2326-6066.CIR-14-0079)
- Chowdhury, R. et al. 2015. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget 6 (2), pp.715-731. (10.18632/oncotarget.2711)
- Webber, J. P. et al. 2015. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 34 (3), pp.290-302. (10.1038/onc.2013.560)
- Spary, L. K. et al. 2014. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+PD-L1+phenotype in prostate cancer. OncoImmunology 3 (9) e955331. (10.4161/21624011.2014.955331)
- Spary, L. K. et al. 2014. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. The Journal of Immunology 192 (7), pp.3101-3110. (10.4049/jimmunol.1302736)
- Webber, J. et al. 2014. Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (SOMAscanTM) platform. Molecular and Cellular Proteomics 13 (4), pp.1050-1064. (10.1074/mcp.M113.032136)
- Al-Taei, S. et al. 2013. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunology, Immunotherapy 62 (12), pp.1821-1830. (10.1007/s00262-013-1488-5)
- Al-Taei, S. et al. 2012. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer 77 (2), pp.312-318. (10.1016/j.lungcan.2012.03.008)
- Clayton, A. et al. 2011. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. The Journal of Immunology 187 (2), pp.676-683. (10.4049/jimmunol.1003884)
- Webber, J. P. et al. 2010. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Research 70 (23), pp.9621-9630. (10.1158/0008-5472.CAN-10-1722)
- Tabi, Z. et al. 2010. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. The Journal of Immunology 185 (2), pp.1330-1339. (10.4049/jimmunol.1000488)
- Mitchell, P. J. et al. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7 (4), pp.n/a. (10.1186/1479-5876-7-4)
- Navabi, H. et al., 2009. A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27 (1), pp.107-115. (10.1016/j.vaccine.2008.10.024)
- Renneson, J. et al., 2009. IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection. European Journal of Immunology 39 (10), pp.2789-2799. (10.1002/eji.200939414)
- Clayton, A. et al. 2008. Human tumor-derived exosomes down-modulate NKG2D expression. Journal of Immunology 180 (11), pp.7249-7258.
- Coleman, S. L. et al. 2008. SV40 large T antigen-specific human T cell memory responses. Journal of Medical Virology 80 (8), pp.1497-1504. (10.1002/jmv.21216)
- Mitchell, J. P. et al. 2008. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. Journal of Immunological Methods 335 (1-2), pp.98-105. (10.1016/j.jim.2008.03.001)
- Clayton, A. et al. 2007. Human tumour-derived exosomes selectively impair lymphocyte responses to Interleukin-2. Cancer Research 67 , pp.7458-7466. (10.1158/0008-5472.CAN-06-3456)
- Clayton, A. et al. 2005. Induction of heat shock proteins in B-cell exosomes. Journal of Cell Science 118 (16), pp.3631-3638. (10.1242/jcs.02494)
- Coleman, S. L. et al. 2005. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Research 65 (15), pp.7000-7006. (10.1158/0008-5472.CAN-04-3792)
- Adams, M. et al., 2005. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23 (17-18), pp.2374-2378. (10.1016/j.vaccine.2005.01.014)
- Navabi, H. et al., 2005. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells, Molecules, and Diseases 35 (2), pp.149-152. (10.1016/j.bcmd.2005.06.008)
- Jasani, B. et al. 2005. Assessment of immunological competence and SV40 specific recall immunity in malignant pleural mesothelioma. Vaccine 23 (17-18), pp.2339-2402. (10.1016/j.vaccine.2005.01.019)
- Clayton, A. and Tabi, Z. 2005. Exosomes and the MICA-NKG2D system in cancer. Blood Cells, Molecules, and Diseases 34 (3), pp.206-213. (10.1016/j.bcmd.2005.03.003)
- Moutaftsi, M. et al., 2004. Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. Journal of Virology 78 (6), pp.3046-3054. (10.1128/JVI.78.6.3046-3054.2004)
- Moutaftsi, M. et al., 2002. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 99 (8), pp.2913-2921. (10.1182/blood.V99.8.2913)
- Tabi, Z. , Moutaftsi, M. and Borysiewicz, L. K. 2001. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens. The Journal of Immunology 166 (9), pp.5695-5703.
Book sections
- Tabi, Z. 2009. Cancer vaccines. In: Lu, Y. and Mahato, R. I. eds. Pharmaceutical Perspectives of Cancer Therapeutics. London: Springer. , pp.365-368.
- Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2.Springer. , pp.129-160. (10.1007/978-1-4020-8442-3)